Cartesian Therapeutics, Inc. (RNAC)
| Previous close | 15.77 |
| Open | 16.16 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 15.82 - 18.14 |
| 52-week range | 11.66 - 42.60 |
| Volume | |
| Avg. volume | 139,130 |
| Market cap | 376.351M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -56.06 |
| Earnings date | 15 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.67 |
Investor's Business DailyCartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs
Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.
GlobeNewswireCartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertiseGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise
- GlobeNewswire
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $130.0 million to the Company, before deducting placement agent fees and other offering expenses.
